PMID- 20685634
OWN - NLM
STAT- MEDLINE
DCOM- 20101202
LR  - 20221207
IS  - 1973-9478 (Electronic)
IS  - 1120-009X (Linking)
VI  - 22
IP  - 4
DP  - 2010 Aug
TI  - Low dose fractionated cisplatin plus gemcitabine for elderly patients with 
      advanced non small cell lung cancer: a retrospective analysis.
PG  - 275-9
AB  - The aim of the study was to evaluate safety and efficacy of gemcitabine-cisplatin 
      in elderly patients with advanced non small cell lung cancer (NSCLC). This study 
      included 59 patients aged >70 years consecutively admitted to our Department. 
      treatment consisted of gemcitabine 1000 mg/m(2) on days 1 and 8, and low-dose 
      fractionated cisplatin 20 mg/m(2) on days 1, 2, 3 of a 21-day cycle. Toxicity was 
      graded according to the world Health Organization (WHO) criteria.A total of 281 
      cycles was administered. Hematological toxicities of grade 3 and 4 were seen in 
      17% and 5% of patients, respectively. Grade 3 gastrointestinal toxicity was 3%, 
      grade 2 neuropathy was 2%. Twenty-nine partial responses with an objective 
      response rate of 49% were obtained. No complete responses were observed. The 
      median progression-free survival (PFS) and overall survival (OS) were 7.8 and 
      15.5 months respectively. Cisplatin-based combination chemotherapy at low doses 
      appears to be safe and active in older patients with advanced NSCLC.
FAU - Pezzuolo, D
AU  - Pezzuolo D
AD  - Department of Oncology, USL1, Massa Carrara, Italy.
FAU - Pennucci, M C
AU  - Pennucci MC
FAU - Mambrini, A
AU  - Mambrini A
FAU - Pacetti, P
AU  - Pacetti P
FAU - Orlandi, M
AU  - Orlandi M
FAU - Tartarini, R
AU  - Tartarini R
FAU - Del Freo, A
AU  - Del Freo A
FAU - Cantore, M
AU  - Cantore M
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Chemother
JT  - Journal of chemotherapy (Florence, Italy)
JID - 8907348
RN  - 0W860991D6 (Deoxycytidine)
RN  - Q20Q21Q62J (Cisplatin)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology
MH  - Cisplatin/administration & dosage/adverse effects
MH  - Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Neoplasm Staging
MH  - Retrospective Studies
MH  - Gemcitabine
EDAT- 2010/08/06 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/08/06 06:00
PHST- 2010/08/06 06:00 [entrez]
PHST- 2010/08/06 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 10.1179/joc.2010.22.4.275 [doi]
PST - ppublish
SO  - J Chemother. 2010 Aug;22(4):275-9. doi: 10.1179/joc.2010.22.4.275.